Annual results confirm a classic cash-burning CAR-T launch: AUCATZYL revenue is real but COGS and SG&A overwhelm it, and the going-concern warning puts pressure on management to raise equity or partner. Watch for financing announcements (equity/debt/collaboration) that could dilute or save the stock. The Q4 10-Q in August 2026 will show if the cash runway estimates hold. Any update on EU market entry pathway or a partnership for autoimmune indications would be a positive catalyst.
Price Chart
Executive Summary
Autolus Therapeutics published its 2025 UK Annual Report, revealing $55.983M in first-year AUCATZYL US sales, a £222.656M net loss, and a 'material uncertainty' going-concern qualification from its auditors, Ernst & Young. The company's cash runway extends into October 2027 under base-case assumptions, but only to June 2027 under stress-testing; management is actively pursuing new financing. As a routine filing of audited annual results with no new regulatory or corporate events, the 8-K transmission is neutral, but the embedded financials reveal a clear negative trend: the company posted its largest-ever loss while burning cash at an accelerating rate.
Key Facts
- FY2025 product revenue (AUCATZYL) was £55.983M (USD ~$73M) vs. £0 in FY2024
- FY2025 net loss widened to £222.656M from £161.035M in FY2024
- Costs exceeded revenue: cost of sales £77.644M; SG&A £100.772M; R&D £84.508M
- Cash & equivalents of £77.393M plus marketable securities of £146.100M at 12/31/2025
- Auditor Ernst & Young flagged a 'material uncertainty' going-concern opinion; cash runway to Oct 2027 base / June 2027 stress
- Net cash used in operating activities was £91.967M in 2025 vs. £469.241M in 2024 (prior-year includes a large securities purchase)
- Blackstone/BioNTech royalty liabilities stood at £208.250M (up from £197.926M in 2024)
- Paid £1.5M in BioNTech revenue-share in 2025; MCSA option (BioNTech co-promote) expired unexercised on 6 Aug 2025
- EU launch 'on hold'; no EU AUCATZYL sales anticipated in 2026
- 13% workforce reduction announced 29 Apr 2026, costing ~£6.0M in severance
- EU marketing authorization triggered a £6.0M milestone payment to UCLB
- EPS: -£0.84 basic and diluted vs. -£0.63 in FY2024; share count 266.1M (weighted) vs. 255.2M
Financial Impact
FY2025 net loss of £222.7M (≈$292M) on revenue of £56.8M; product COGS of £77.6M significantly exceeded revenue; cash burn of ~£92M in operations; $389M market cap burns nearly its entire liquidity annually
Risk Factors
- Going-concern uncertainty – must raise additional funding within 12-16 months or risk liquidity crisis
- EU launch on hold with no revenue expected in 2026, capping total addressable market
- Product COGS exceeded revenue; manufacturing cost-reduction plan (Nucleus scaling) may take quarters to achieve
- Blackstone and BioNTech royalty obligations (~£208M liability) represent a structural cash drain
- Inventory write-downs of £9.2M suggest demand forecasting or shelf-life challenges
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001730463-26-000069 |
| Exhibit: ex992noticeofagm2026.htm | 0001730463-26-000069 |
| Exhibit: ex993formofproxy.htm | 0001730463-26-000069 |
| Document: autl-20260605.htm | 0001730463-26-000069 |
| Document: 0001730463-26-000069-index-headers.html | 0001730463-26-000069 |
| Document: 0001730463-26-000069-index.html | 0001730463-26-000069 |
| Document: 0001730463-26-000069.txt | 0001730463-26-000069 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 12, 2026 20d ago | S-3 | $1.94 $1.94 | · 0.00% | ▼ −0.11% | $1.78 (−8.25%) |
Aug 11, 2026 7w ago | 8-K | $2.33 $2.29 | ▼ −1.72% | ▼ −1.31% | $1.78 (−23.61%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Aug 3, 2026 8w ago | 8-K | $1.82 $2.07 | ▲ +13.74% | ▲ +11.71% | $1.78 (−2.20%) |
Jun 12, 2026 16w ago | Press Release | $1.56 $1.51 | ▼ −3.21% | ▼ −3.88% | $1.78 (+14.10%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.56 $1.53 | ▲ +1.92% | ▲ +2.36% | $1.78 (−14.10%) |
Jun 9, 2026 16w ago | 8-K | $1.46 $1.50 | ▼ −2.74% | ▼ −0.33% | $1.78 (−21.92%) |
May 21, 2026 19w ago | Press Release | $1.70 $1.84 | ▲ +8.24% | ▲ +6.58% | $1.78 (+4.71%) |
May 14, 2026 20w ago | 8-K | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
May 14, 2026 20w ago | Press Release | $1.59 $1.65 | ▲ +3.77% | ▲ +4.49% | $1.78 (+11.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access